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CCL22 to Activate Treg Migration and Suppress
Depigmentation in Vitiligo
Jonathan M. Eby1,4, Hee-Kap Kang1,4,5, Sean T. Tully1, Wendy E. Bindeman2, Daniel S. Peiffer1,
Shilpak Chatterjee3, Shikhar Mehrotra3 and I. Caroline Le Poole1
In vitiligo, gradual cutaneous depigmentation and cytotoxic T-cell activity against melanocytes are accompanied by a
paucity of regulatory T cells (Tregs) in vitiligo patient skin, indicating that autoimmune responses are not adequately
held in check. Thus, we sought a means to repopulate patient skin with Tregs. We hypothesized that enhanced
expression of CCL22 can promote Treg skin homing to suppress depigmentation. The mouse Ccl22 gene was cloned
into an expression vector and resulting DNA was used for gene gun treatment. Two spontaneous depigmentation
models with different kinetics of melanocyte loss were utilized, expressing tyrosinase-reactive and gp100–reactive
TCR transgenes. Mice were subjected to five gene gun treatments 6 days apart, scanned for depigmentation weekly
thereafter, and monitored for activation and proliferation of relevant T cells and for Treg infiltration to the skin.
Significantly reduced depigmentation 2 weeks after treatment was accompanied by a markedly increased abundance
of Tregs in the skin at the expense of melanocyte-reactive, TCR transgenic T cells, as well as by reduced proliferation
and reduced IFN-g production in response to cognate peptide. Continued treatment may be necessary for sustained,
local immunosuppression. These findings suggest that topical CCL22 may be used for the treatment of vitiligo.
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INTRODUCTION
Vitiligo patients develop gradual skin depigmentation (Le Poole
and Boissy, 1997). The disease has a prevalence of B0.5%,
with little evidence for gender preference or for an association
with particular skin tones (Tour et al., 2014). The velocity of
depigmentation varies among patients, and disease progression
is thought to accelerate under stress (Jeon et al., 2014). On
average, however, patients lose B1% of pigmentation each
year (Cedercreutz et al., 2010). Although the disease is triggered
by stressful events that can directly harm melanocytes, progres-
sive depigmentation involves cytotoxic activity by melanocyte-
reactive T cells (Le Poole et al., 1996). Once the melanocytes
are destroyed, the immune response resolves as well.
To understand why melanocyte-reactive T cells mediate
depigmentation in vitiligo, whereas the same triggers applied
to control individuals will not initiate disease, regulatory
immune mechanisms should be considered. Even desirable
immune responses to infectious organisms should dissolve
once an infection is cleared (Mittru¨cker and Kaufmann, 2004).
To accomplish such regulatory activity, a subset of T cells
(regulatory T cells or Tregs) can secrete IL-10, suppress T-cell
proliferation, and prevent activation of other components of
the immune response (Ozdemir et al., 2009).
Tregs are characterized by expression of the FoxP3 transcrip-
tion factor, high levels of surface CD25 for IL-2 uptake, and other
surface molecules involved in immunosuppressive functions,
including the glucocorticoid-induced tumor necrosis factor
receptor–related protein or GITR (Taams and Akbar, 2005). In
several autoimmune diseases, a reduction in the number of
regulatory CD4þCD25þFoxP3þ T cells has been reported
(Pellerin et al., 2014). In vitiligo, a limited number of Treg is
found in the skin, signifying a reduced ability to hold local
immune responses in check (Klarquist et al., 2010); reduced Treg
numbers were found not only in lesional, but also in non-lesional
and peri-lesional vitiligo skin. Although others have reported
limited circulating Treg numbers (Lili et al., 2012), our
observations were consistent with a biologically insignificant
increase in circulating Treg. Questioning why Treg do not readily
migrate toward vitiligo skin, we found a remarkable reduction in
the number of CCL22-producing cells (Klarquist et al., 2010).
CCL22 is commonly secreted by mast cells, macrophages, and
inflammatory dendritic cells (Shimura et al., 2010) and is a
known ligand of CCR4. This receptor is found on Th2 cells,
supportive of humoral responses, and on Treg (Yoshie and
Matsushima, 2014).
We thus proposed to develop proof of concept for the idea,
that overexpression of Ccl22 in the skin can recruit Treg, and
provide a therapeutic platform to treat vitiligo. An advantage to
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treat vitiligo is that, in this autoimmune disease, the target organ
is external and can be directly accessed while simultaneously
monitoring disease. Here we have made use of mouse models
that develop progressive vitiligo because of a transgenic TCR
reactive with melanocytes. In Pmel-1 mice, T cells respond to a
gp100–derivative peptide (Hwang et al., 2006); some
spontaneous depigmentation of the pelage is observed beyond
20 weeks, and vitiligo will develop slowly. Spontaneous disease
will also develop in h3TA2 mice with a TCR transgene reactive
with human tyrosinase (Mehrotra et al., 2012), but the disease
will develop much more rapidly than in Pmel-1 mice, starting at
4 weeks of age. Finally, we treated wild-type mice to perform
immune monitoring experiments; to locally overexpress Ccl22
in mice, we fired Ccl22-encoding plasmid DNA via biolistic
gene gun into naired ventral skin to achieve rapid and focal
overexpression of the chemokine. The concept is illustrated in
Supplementary Figure S1. We repeatedly gene gun treated mice
using an expression vector encoding mouse Ccl22 and followed
depigmentation by flatbed scanning. We also measured che-
mokine overexpression and followed by Treg skin infiltration to
treated skin. Immunosuppression was further measured among
splenocytes to understand whether Treg can alleviate vitiligo
symptoms via an overabundance of the chemokine Ccl22.
Immediate and longer-term effects of gene gun–mediated
Ccl22 overexpression were measured. Splenocytes from
Ccl22-treated mice were incubated with cognate peptide to
measure resulting T-cell responses by IFN-g ELISPOT and by
proliferation assays using 3Hthymidine incorporation. Our find-
ings have direct implications for vitiligo treatment, will provide
insight into the central role Tregs have in autoimmune disease,
and can be readily extended to other skin immune disorders.
RESULTS
Depigmentation is markedly reduced by Ccl22 DNA treatment
First, we evaluated the effects of Ccl22 DNA treatment on
depigmentation observed in vitiligo-prone mice. Mice expressing
a melanocyte-reactive TCR transgene were repeatedly gene gun
treated by shooting DNA-coated bullets into naired ventral skin to
achieve Ccl22 overexpression. When treating h3TA2 mice that
normally develop rapid vitiligo already apparent in mice 5 weeks
of age (Mosenson et al., 2013), reduced depigmentation was
observed in vitiligo-prone animals after the pelage returned. The
example shown in Figure 1a illustrates the profound effect that
Ccl22-encoding DNA has on depigmentation, with animals in the
control group almost fully depigmented, whereas just over half of
pigmentation remained in Ccl22-treated mice. In Figure 1b,
depigmentation was quantified as 57.6±19.0% in the control
group (n¼ 6) and 37.0±18.1% in the Ccl22-treated group (n¼7),
and thus 64.2% of the original depigmentation was prevented in
response to Ccl22-encoding DNA (P¼ 0.036). This experiment
was executed 3 times with similar results, including 13 animals in
all. Animals from each treatment series are included in the
analysis. In Figure 2, the experiment was repeated in Pmel-1
mice representing a slowly depigmenting model. Representative
mice are shown before the fourth treatment in Figure 2a, and
depigmentation is quantified in Figure 2b where treatment restored
46.4% of the original pigment loss when compared with empty
vector–treated control animals evaluated at 19.9±20.3% (n¼ 11)
and 37.1±18.3% (n¼ 8) depigmentation of regrowing hair,
respectively (P¼0.037). Remarkably, upon reassessment 2 weeks
after the fifth and final treatment as shown in Figure 2c, the
differences between the Ccl22-treated (51.0±36.7%, n¼ 10) and
control groups (73.6±27.7%, n¼7) were no longer significant
(P¼ 0.09). Taken together, we conclude that Ccl22 DNA treat-
ment can markedly prevent depigmentation; yet, continued
treatment is required to maintain a therapeutic effect.
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Figure 1. Significantly reduced depigmentation in h3TA2 mice. Mice were
treated with Ccl22-encoding or empty vector (EV) DNA five times, 6 days
apart, and depigmentation was evaluated after hair regrowth when animals
were 11 weeks of age. (a) Representative mice from each group are shown and
(b) results were quantified. Note markedly (35.8%) reduced depigmentation in
Ccl22-treated animals (n¼ 6 (EV), n¼7 (Ccl22), *Po0.05).
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Figure 2. Ccl22 DNA treatment markedly reduced depigmentation among
aging Pmel-1 mice. Twenty-one week old mice were treated with murine
Ccl22-encoding DNA or empty vector (EV) alone for 5 weeks just at the onset
of depigmentation, and were imaged when the pelage returned, 2 weeks after
the final treatment. (a) Depigmentation in representative mice after treatment.
(b) Quantification in all mice evaluated, showing 46.4% reduced depigmenta-
tion among treated animals 3 weeks after the last treatment (n¼8 (EV), n¼11
(Ccl22), *Po0.05). (c) Continued treatment is required for prolonged inhibition
of depigmentation, as shown by re-evaluation of the mice under b. Six weeks
after the last treatment (n¼7 (EV), n¼ 10 (Ccl22), P¼ 0.09). The relatively
slow depigmentation process in the Pmel-1 mice allows for a solid comparison
of depigmentation at different post-treatment periods.
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DNA treatment elevates Ccl22 expression in treated skin
DNA treatment with an expression plasmid encoding Ccl22
cDNA should result in markedly enhanced Ccl22 expression
within the skin; here we assessed the lasting effects of Ccl22-
encoding DNA treatment on Ccl22 expression. Initially, wild-
type C57BL/6 mice were gene gun treated five times, 5 days
apart with 4.8mg of Ccl22-encoding expression vector DNA
before harvesting skin tissue to establish chemokine expression
levels resulting from treatment. As shown in Figure 3a, a
remarkable difference between empty vector DNA–treated and
Ccl22-treated mice was observed, with chemokine expression
virtually absent from untreated mouse skin, whereas an increase
from 5.4±4.6, n¼ 3 to 73.7±32.1, n¼ 3 cells per mm2,
representing a 13.9-fold increase, was observed after Ccl22
treatment. These differences are further illustrated in Figure 3b
and c, showing empty vector DNA–treated skin compared with
the skin from a Ccl22-treated mouse. Prompted by these results,
we likewise probed the skin of Pmel-1 mice harvested 14 days
after the final treatment. In Figure 3d–f, a 5.2-fold increase from
11.6±2.4 (n¼ 6) to 60.4±39.16 (n¼6) cells per mm2 in Ccl22
expressing cells is maintained (P¼0.014), although differences in
depigmentation were no longer significant by then (Figure 2).
These findings indicate that a prolonged period of highly elevated
Ccl22 expression is required to keep depigmentation at bay.
Ccl22 treatment enhances Treg recruitment
Overexpression of Ccl22 in the skin will generate a chemokine
gradient that can support Treg recruitment to the treatment site.
Treg abundance in the skin of treated mice was initially evaluated
in skin samples of the h3TA2 strain. Recruitment of Treg was
markedly increased following Ccl22 treatment, significantly rais-
ing the abundance of FoxP3þ , CD3þ Treg as measured by
immunoenzymatic double staining, and single stainings per-
formed with an antibody to CD25 instead of FoxP3 further
supported these findings (not shown). Immunofluorescence was
also used to locate CD3þFoxP3þ cells in the skin of aging Pmel-
1 mice treated for 5 weeks and harvested 2 weeks after the final
treatment. Double-stained cells appear as yellow in the images
(arrows: examples), and these cells were 14.9-fold more abundant
after treatment with Ccl22-encoding DNA at 7.34±3.39cells per
mm2 compared with 0.49±0.86cells per mm2 in response to
empty vector DNA (Figure 4a, n¼3, P¼ 0.033). Finally, Treg
abundance was measured among splenocytes of treated Pmel-1
mice 2 weeks after the final treatment. Of note, peripheral Treg
percentages evaluated by fluorometric measurement of FoxP3/
CD3 expression analysis of splenocytes shown in Figure 4e were
not significantly increased (P¼0.08) by Ccl22 treatment, at
average Treg percentages among total T cells of 2.2±1.5% in
the empty vector group (n¼ 4) compared with 3.7±1.3% in the
Ccl22 group (n¼ 5) in the spleens of treated mice. These results
suggest that Ccl22 treatment results in enhanced Treg recruitment
and a trend towards increased systemic Treg levels, associated
with enhanced abundance of Treg in the skin.
Enhanced abundance of Treg corresponds to a decreased
presence of melanocyte-reactive T cells in treated skin
As an initial measure of Treg function, we evaluated the indirect
effects on effector T-cell abundance in the skin of rapidly
depigmenting mice. In vitiligo-prone, h3TA2 mice, melanocyte-
reactive T cells that eliminate melanocytes from the skin are
readily detectable by immunostaining for the TCR. Reduced
abundance of Vb12-expressing T cells in Ccl22-treated mice is
illustrated in Figure 5, and the number of melanocyte-reactive T
cells is quantified among three mice per group using skin
samples of h3TA2 mice available 3 weeks after the final
treatment, when mice were 8 weeks of age. Although Tregs also
express the transgenic TCR (Supplementary Figure S2), the Treg
cohort constitutes a negligible subset of the total Vb12 expressing
T-cell numbers observed. The abundance of effector T cells is
36.4% reduced in the skin of Ccl22-treated mice at 35.7±
8.2cells per mm2 compared with empty vector–treated mice at
56.2±1.0 cells per mm2 (n¼3, P¼ 0.024). As CCR4 expression
is generally lower among effector T cells when compared with
Treg, these data are best explained as an indirect effect of Ccl22
treatment on increased Treg abundance, suppressing effector
T-cell recruitment to and proliferation within the skin.
Enhanced regulatory function is observed in Ccl22-treated mice
Given the favorable Treg to effector T-cell ratio in the skin of
Ccl22 DNA–treated mice as implied by the abundance of Treg
as a percentage of total T cells, associated with reduced
depigmentation, we performed functional assays to measure
effector functions in treated animals. Splenocytes were
harvested from mice treated with Ccl22-encoding or empty
vector DNA, and cells were incubated with cognate peptide
before quantification of IFN-g-secreting T cells by ELISPOT.
Representative examples of cytokine-releasing T cells among
samples derived from mice either Ccl22 DNA–treated, or empty
vector DNA–treated h3TA2 mice incubated with cognate epi-
tope peptide, hTyr368–376, are shown in Figure 6a next to
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Figure 3. Ccl22 treatment increases Ccl22 expression in treated skin. C57BL/6 mice were treated with Ccl22-encoding expression vector DNA five times before
harvesting skin tissue 14 days after the final treatment. (a) The number of Ccl22-expressing cells was 13.9-fold increased in treated skin samples (n¼3 (empty
vector (EV) and Ccl22), *Po0.05). (b) Ccl22 staining before and (c) after treatment. In (d), Ccl22-expressing cells were quantified in the skin of treated Pmel-1 mice,
again showing an increase of 5.2-fold (n¼ 6 (EV), n¼ 6 (Ccl22), *Po0.05), with (e) EV-treated skin and (f) Ccl22-treated skin examples. Scale bar represents 48mm.
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quantified ELISPOTS to compare effector functions among both
populations, harvested 3 weeks after the last DNA treatment,
showing 75.2% reduced T-cell activation among the Ccl22-
treated group at 63.4±45.7 spots per well compared with
255.5±86.2 spots per well in the empty vector control group
(n¼4, P¼ 0.007). A sample of splenocytes was likewise
subjected to proliferation measurements as shown in Figure 6c.
With measurements ranked in order of decreasing proliferation,
the latter data correspond directly to the ranking of samples in
order of an decreasing number of IFN-g-releasing T cells in
Figure 6b. These data support a markedly decreased effector
function among vitiligo-prone, h3TA2 mice treated with Ccl22.
DISCUSSION
The role of CCL22 in disease pathology has been under
investigation. We recently demonstrated that a quantitative
increase in Treg can control vitiligo (Chatterjee et al., 2014). In
follow-up to our original report of reduced CCL22 expression
in vitiligo skin (Klarquist et al., 2010), we proposed that
overexpression of CCL22 in depigmenting skin might halt
disease progression. This would render patients eligible for
repigmentation treatment by autologous transplantation and
other means currently available (Wassef et al., 2013). For
proof of principle, we overexpressed murine Ccl22 in mouse
models of vitiligo. Our data convincingly show that continued
expression of the chemokine interferes with disease progres-
sion by recruiting Treg to suppress ongoing T-cell-mediated
cytolytic anti–melanocyte responses. To understand the impli-
cations of our findings, findings related to CCL22 expression,
disease development, and treatment should be considered.
Originally known as MDC for ‘‘macrophage derived cytokine’’
(Landi et al., 2014), high MDC expression was shown to
discriminate lymphocyte dense Hodgkins lymphoma from
classic Hodgkins disease, and chemokine overexpression was
held responsible for attracting eosinophils (Hedvat et al., 2001).
Meanwhile, in solid tumors, PGE2 elevates the production of
CCL22, leading to undesirable Treg recruitment (Karavitis et al.,
2012). We and others have reported increased CCR4 expression
by Treg in melanoma (Klarquist et al., 2009, Pigment Cell Mela-
noma Res 22: pp 495 (abstract)); here also, therapeutic opportu-
nities exist, as Abs to CCR4/CCR10 prevent Treg migration into
inflamed skin (Wang et al., 2010; Sugiyama et al., 2013).
By contrast, for a number of autoimmune diseases, investiga-
tors consider reduced CCL22 as a factor in disease pathology.
Newly diagnosed multiple sclerosis patients, for example, display
lowered serum levels of CCL22 (Jafarzadeh et al., 2014). Yet, no
such difference was found in Addison’s disease (Ekman et al.,
2014). Such discrepancies may relate to the predominant
immune mechanism driving either disease, namely T-cell-
mediated versus humoral immunity, involving different
regulatory mechanisms. In this respect, CCL22 is also a Th2
attractant, and its expression correlates with lymphocytic
infiltration in the Sjo¨grens syndrome (Moriyama et al., 2012).
For diseases involving reduced Treg recruitment to affected
tissues, new developments include the use of random amino-acid
copolymers thought to stimulate CCL22 expression by antigen-
presenting cells, which are currently under development for the
treatment of MS (Koenig et al., 2013). Increased CCL22 secretion
can be assigned to dendritic cells, possibly of the CD11bþ
CD11cþ subtype more so than from macrophages in response to
copolymer administration (Kawamoto et al., 2013). For the
current study, the significance of this is that CD11bþCD11cþ
dendritic cells are readily available in vitiligo (Mosenson et al.,
2013). Another strategy advocated to date is adenoviral over-
expression of CCL22 for diabetes treatment, showing successful
Treg recruitment and protection from diabetes development in
NOD mice (Montane et al., 2011). A limitation to its application
for diabetes is the loss of insulin-producing cells from the
pancreas before symptoms arise (La Torre, 2012).
The suggested involvement of CCL22 in autoimmune
disease, including multiple sclerosis, remains controversial,
and the opposite reasoning has also been advocated. As
CCL22 recruits macrophages, anti-CCL22 treatment was used
in a mouse model of MS to delay onset and dampen disease
severity (Dogan et al., 2011). Again, this holds relevance for
vitiligo, as macrophages are likewise abundant in the
perimeter of advancing skin lesions (Le Poole et al., 1996).
What this inhibitory strategy has in common with our DNA
treatment strategy is that both require continued application to
remain efficacious (Dogan et al., 2011; Forde et al., 2011).
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Figure 4. Tregs are increasingly abundant following Ccl22 treatment. Mice were treated with Ccl22-encoding or empty vector (EV) DNA, and skin tissue was
harvested 2 weeks after the final treatment. (a) The number of FoxP3þCD3þ Treg was quantified in the skin of C57BL/6 mice (n¼ 3 (EV and Ccl22), Po0.05) and
representative stainings are shown for (b) EV and (c) Ccl22-treated skin of Pmel-1 mice, again showing (15-fold) enhanced Treg infiltration to the skin among
treated animals (n¼ 6 (EV and Ccl22), *Po0.05). (d) Representative FACS histograms show (e) a trend toward a minor increase in Treg abundance among T cells in
the circulation of h3TA2 mice, as measured among splenocytes (n¼4 (EV), n¼ 5 (Ccl22), P¼0.08). Scale bar represents 48mm.
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Another means of manipulating CCL22 expression can be
administration of vitamin D. Expression of CCL22 is elevated
in response to 1a,25-(OH)(2)D(3), which again can be
therapeutic for T-cell-mediated autoimmune disease but not
humoral autoimmune disease (Kuo et al., 2010). In fact, type 2
cytokines (i.e. IL-4) increase CCL22 secretion, suggesting that
Treg responses are not affected in antibody-mediated auto-
immune disease (Butti et al., 2008). The use of topical vitamin
D3 analogs for the treatment of vitiligo is, however, unlikely to
become mainstream until vitiligo disease activity is better
defined, because responses to such treatment tend to be slow
and thus underappreciated (Parsad and Kanwar, 2009). The
same concept of supporting CCL22 responses to drive Th2
responses (in combination with antigen administration) has
shown promise in Alzheimers (Movsesyan et al., 2008).
Here, we demonstrate that overexpression of Ccl22 in the
skin can help recruit Tregs and leads to suppression of ongoing
depigmentation for the duration of treatment in TCR trans-
genic animal models of vitiligo. This holds true despite
somewhat reduced abundance of Tregs in one of the models
engaged in our studies. As reported previously, the 1383i
receptor expressed in h3TA2 mice functions irrespective of
CD4 or CD8 coreceptor expression (Mehrotra et al., 2012) and
can likewise function in Treg (Brusko et al., 2010).
Taken together, we conclude that inhibition of the
chemokine can be of value for diseases where enhancement
of T-cell-mediated immunity is desirable, whereas forced
overexpression of CCL22 has the potential for vitiligo and
other conditions involving hyperactive T-cell-mediated
immunity. The chemokine is best overexpressed within or in
close proximity to affected tissues, but responses can be
measured away from the application site as well. In this
regard, we measured enhanced Treg recruitment to the skin,
reduced abundance of effector Tells, and suppression of T-cell
effector functions. Whereas DNA-based treatments are gen-
erally met with some hesitation, several applications exist that
show promise for disease treatment. The Treg chemo-attrac-
tant cytokine CCL22 is thus of great interest as a potential
therapeutic for vitiligo in active phases of the disease.
MATERIALS AND METHODS
DNA bullet preparation
Full-length primers to amplify the mouse Ccl22–encoding gene were
50-ATGGCTACCCTGCGTGTCCCACTC-30 and 50-CTAGGACAGTT
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Figure 5. Ccl22 reduces the abundance of melanocyte-reactive T cells in treated skin. (a) The abundance of melanocyte-reactive T cells in the skin was measured
by immunostaining using antibodies to the transgenic TCR-b subunit of h3TA2 mice. Such effector T cells were much more abundant in (b) empty vector (EV)-
treated and (c) 36.4% reduced in Ccl22-treated mice (n¼ 3 (EV and Ccl22), *Po0.05). These data suggest that enhanced Treg infiltration can lead to suppression of
effector T-cell activity and diminished depigmentation in situ. Scale bar represents 48mm.
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Figure 6. Suppressed immune function observed in Ccl22-treated mice in response to Ccl22 DNA treatment. Splenocytes harvested from h3TA2 mice treated
with Ccl22-encoding or empty vector (EV) DNA 3 weeks after the last treatment were incubated with and without cognate peptide for 24 hours. (a) The proportion
of IFN-gamma-secreting cells was measured in the presence of 30mg ml1 peptide as illustrated and (b) was 75.2% reduced in response to Ccl22 (n¼ 4 (EV and
Ccl22), **Po0.01). (c) Proliferation measured by 3H-Thymidine incorporation into h3TA2 cells in response to 10mg ml1 hTyr368–376. Decreased proliferation
aligned with decreased IFN-g secretion in the same samples in b.
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TATGGAGTAGCTTCTTCACCCAG-30. The PCR product was isolated
from gel after amplification of cDNA, prepared using RNA extracted
from cultured B16 melanoma cells CRL-6475 (ATCC, Manassas, VA).
Resulting DNA was ligated into the TA expression vector CT-GFP
TOPO (Invitrogen, Grand Island, NY) and sequenced using a T7 primer
(Invitrogen). This DNA and empty vector control DNA were used to
coat 1mm gold particles (Alfa Aesar, Ward Hill, MA) in the presence of
spermidine (Sigma-Aldrich, St Louis, MO). Expression vector-gold
complexes were used to coat Teflon bullets (Bio-Rad, Hercules, CA),
containing 1mg of expression plasmid DNA each. Bullets were stored
under vacuum desiccation and used within 14 days.
Mouse experiments
Experiments involving mice were conducted as approved by the
Institutional Animal Care and Use Committees of Loyola University
Chicago or the Medical University of South Carolina.
C57BL/6 mice and Pmel-1 mice, transgenic for a gp100–reactive
TCR (Overwijk et al., 2003), were obtained from Jackson Labs (Bar
Harbor, ME). In Pmel-1 mice, the transgenic TCR, which is encoded on
chromosome 2, expresses an H2-Db restricted TCR consisting of Tcra-
V1 and Tcrb-V13 recognizing Pmel-17 amino acids 25–33 by 495%
of CD8 T cells. These mice express FoxP3 among an increased
percentage of CD4 T cells (Quatromoni et al., 2011). A third strain
of mice, h3TA2, is transgenic for a tyrosinase-reactive TCR and for
human HLA-A2 (Mehrotra et al., 2012) and was bred in-house. In these
mice, a transgenic TCR of human origin consisting of TCRa-V4 and
TCRb-V12 expressed by 480% of CD3þ T cells effectively recognizes
the human HLA-A*0201 restricted, tyrosinase-derived peptide 368–
376 and displays cross reactivity toward its mouse homolog. The Treg
population occupies about 2% of the splenocyte population, and their
abundance is B3-fold enriched in the absence of IFN-g (Chatterjee
et al., 2014). The Pmel-1 strain shows spontaneous depigmentation
starting at 6 months of age; h3TA2 mice exhibit rapid spontaneous
depigmentation initiating as early as 4 weeks of age, and these mice
continue to rapidly depigment. All mice were used in experiments at
3–6 mice per group as indicated. Most animals were treated starting at
5 weeks of age; some groups of Pmel-1 mice, however, were treated
starting at 21 weeks of age. At least three repeat experiments were
performed for each mouse strain. Mice were ventrally naired (Church
& Dwight, Ewing, NJ) as needed and treated five times using empty
vector–coated bullets or Ccl22-encoding bullets prepared as described
above, 4.8mg DNA every 5 days. To test the role of Ccl22 in an
inducible vitiligo model (Denman et al., 2008), C57BL/6 mice were
treated with bullets containing both epitope-optimized TRP-1ee/ng-
encoding DNA (Guevara-Patin˜o et al., 2006) as an immunogen and
Ccl22-encoding DNA, whereas the control group received the same
TRP-1-encoding DNA combined with empty vector DNA. Wild-type,
C57BL/6 mice were included solely to test whether Ccl22
overexpression and Treg migration can likewise be impacted in
animals not naturally prone to develop depigmentation.
Treg proliferation assays
Splenocytes (5 105) from h3TA mice treated with Ccl22-encoding
or empty vector DNA were cultured in 96-well microculture plates in
RPMI-1640 containing 0.5% syngeneic mouse serum and 5 10 5
M 2-mercaptoethanol. Triplicate cultures were stimulated with
10mg ml 1 of cognate peptide (tyrosinase368–376) for 72 h. Cultures
were then pulsed with 1mCi of 3H-thymidine (ICN Biochemicals,
Costa Mesa, CA) and harvested 18 h later. Measurements of
3H-thymidine incorporation into DNA were expressed as D cpm
(¼ counts per minute in response to cognate peptide stimulation
counts per minute of unstimulated control samples).
Depigmentation analysis
Depigmentation was measured in mice receiving Ccl22-encoding
DNA or vector only, starting 2 weeks after the final treatment as hair
returned. Depigmentation was followed for 6 weeks. Mice were
placed on a flatbed scanner (Hewlett-Packard Company, Palo Alto,
CA) and the ventral or dorsal sides of the mice were imaged. The
images were captured in Adobe Photoshop Software (Adobe Systems,
San Jose, CA). Histograms were prepared essentially as described,
displaying mice before treatment to capture a cutoff point incorporat-
ing 95% of pixels to reflect pigmented pelage (to allow for small areas
not covered by pigmented hair). The increase in the proportion of
pixels crossing the cutoff value reflects the % depigmentation of mice
after treatment (Denman et al., 2008).
ELISPOT analysis, fluorocytometry, and immunohistochemistry
Cytokine production was measured directly from cultured splenocytes
of treated mice. We quantified peptide-reactive T cells by ELISPOT
kits (MABTECH, Mariemont, OH). Briefly, plates were coated with
capture anti-IFN-g antibodies. Splenocytes (5x105 cells/well) were
cultured in RPMI-1640 plus 10%FBS in the presence of up to
30mg ml 1 cognate peptides (Pi Proteomic, LLC, Huntsville, AL) or
PBS. After 24 h, cytokine-secreting cells were detected using biotiny-
lated anti–cytokine antibodies, followed by horseradish peroxidase–
conjugated streptavidin (MABTECH) and 3-amino-9-ethylcarbazole
substrate (Sigma-Aldrich). Cytokine-secreting cells were quantified
using ELISPOT equipment (Cellular Technology, Cleveland, OH).
Results were compared for animals treated with and without Ccl22-
encoding DNA for the treated mice.
Meanwhile, the skin harvested from treated animals was originally
snap frozen and stained for Ccl22. The number of Ccl22-expressing
cells per area was compared for mice that were or were not treated
with Ccl22-encoding DNA. For comparison, spleens were snap
frozen and 8mm cryosections were fixed in 4% paraformaldehyde
and subjected to Ccl22 immunostaining using FITC-labeled primary
antibodies (ABCD1, Bioss, Woburn, MA). We also stained the skin
with antibodies to CD3 (FITC-labeled 145-2C11; BD Pharmingen), to
human Vb12 binding to the tyrosinase-reactive TCR (FITC-labeled
511; Thermo Scientific, Hanover Park, IL), and FoxP3 (Biotin-labeled
FJK-16s; eBioscience, Sand Diego, CA) with subsequent detection
using streptavidin-PE (Southern Biotech, Birmingham, AL) to quantify
total T-cell infiltration and Treg populations in the skin. Fluorescent
cells were captured using an Olympus AX80T Microscope (Melville,
NY), and images were analyzed in Adobe Photoshop to quantify the
number of stained cells and the tissue area in 49 images per staining.
Cell surface markers were evaluated among red blood cell–
depleted splenocytes from a 6-week-old h3T, TCR transgenic mouse
using antibodies CD3-APC-Cy7 (145-2C11; BioLegend, San Diego,
CA), CD25-PerCp-Cy5.5 (PC61; BD Biosciences), CCR4-PE-Cy7
(2G12; BioLegend), and Vb12-FITC (511; Thermo Scientific). For
intranuclear detection of transcription factor FoxP3, paraformalde-
hyde-fixed splenocytes were incubated in the presence of 0.3%
saponin and FoxP3-APC (FJK-16s; eBioscience) antibody before being
detected on a LSR-II flow cytometer (BD Biosciences).
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Statistics
Data were presented as mean±SD throughout the manuscript and
analyzed for statistical significance of differences among two groups
using Student’s t-tests accounting for unequal variance.
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